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Background: The median age of newly diagnosed patients with non-small cell lung cancer (NSCLC) is 67 years,
and one-third of patients are older than 75 years. Elderly patients are more vulnerable to the adverse effects of
chemotherapy, and targeted therapy might thus be a relevant alternative. The objective of this study was to assess
the cost-effectiveness of erlotinib followed by chemotherapy after progression, compared to the reverse strategy, in
fit elderly patients with advanced NSCLC participating in a prospective randomized phase 2 trial (GFPC0504).
Methods: Outcomes (PFS and overall survival) and costs (limited to direct medical costs, from the third-party payer
perspective) were prospectively collected until second progression. Costs after progression and health utilities
(based on disease states and grade 3–4 toxicities) were derived from the literature.
Results: Median overall survival, QALY and total costs for the erlotinib-first strategy were respectively 7.1 months,
0.51 and 27 734 €, compared to 9.4 months, 0.52 and 31 688 € for the chemotherapy-first strategy. The Monte Carlo
simulation demonstrates that the two strategies do not differ statistically.
Conclusion: In terms of cost effectiveness, in fit elderly patients with NSCLC, erlotinib followed by chemotherapy
compares well with the reverse strategy.
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The US National Institutes of Health estimated that $89
billion was spent on cancer care in the United States in
2007, and that the total economic burden reached
$219.2 billion when indirect costs associated with lost
productivity and death were taken into account. Recent
trends suggest that the growth in cancer spending will
accelerate, owing to costly new treatments and the in-
creasing number of cancer patients. These costs may* Correspondence: Christos.chouaid@sat.aphp.fr
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reproduction in any medium, provided the orincrease further still with the introduction of novel tar-
geted therapies [1]. Lung cancer is the second most
common malignancy in the US and the leading cause of
cancer-related death. Non small-cell lung cancer
(NSCLC) accounts for 85% of lung cancers, and most
patients already have advanced or metastatic disease at
diagnosis [2]. Between 30% and 40% of NSCLC cases are
diagnosed in patients over 70 years of age, raising spe-
cific issues of age, comorbidity and toxicity [3]. Most
elderly patients are either under-treated or receive non
validated schedules [3,4]. They are also largely under-
represented in therapeutic trials, and little clinical re-
search takes their specificities into account [4]. The
value of specific studies of elderly subjects has beenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Model inputs
Estimates Low High Source
Health state utilities 0.673 0.27 0.80 [16,17]
Stable disease on oral therapy 0.653 0.26 0.78 [16,17]
Stable disease on IV therapy 0.473 0.19 0.56 [16,17]
Progressive disease 0 [16,17]
Death
Cost of medical services and drugs (€) 2174.7 1627 3021 [12,13]
Erlotinib 30 days supply (150 mg) 9.1/mg [12,13]
Docetaxel 0.2/mg [12,13]
Gemcitabine 368 [12,13]
Hospitalization at home (day) 422 [12,13]
Day-ward hospital 557.40 [12,13]
G-CSF injection (per cycle) 220.53 [12,13]
Erythropoietin (per injection) 2324 [15]
Palliative care after progression
(per month)
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treatment for patients under 65 with metastatic NSCLC
and good performance status consists of dual-agent plat-
inum-based chemotherapy. There is no consensus on
the management of elderly NSCLC patients, although
adapted platinum-based chemotherapy seems feasible
in high selected subjects [4-6]. Single-agent and dual-
agent therapy without a platinum salt also seems pos-
sible for patients selected on the basis of a geriatric
assessment taking comorbidities into account. Among
the available non platinum-based chemotherapy regi-
mens, the docetaxel-gemcitabine (DG) combination is
considered one of the most promising [7-9]. Targeted
therapies have given promising results in elderly popu-
lations. In the pivotal BR21 study, second-line erlotinib
had the same efficacy in the subgroup of patients over
70 years old as in the entire population [10]. Targeted
therapies are also a potential first-line option for elderly
patients with advanced NSCLC [11]. Indeed, erlotinib
was well tolerated in this population and there was a
significant improvement in key symptoms [11]. One
difficulty in this setting is the heterogeneity of elderly
populations. The use of a co-morbidity score and a
comprehensive geriatric assessment (CGA) can identify
a more homogenous group of fit elderly patients [9].
The objective of this cost analysis was to assess the
cost-effectiveness of first-line erlotinib followed by
chemotherapy after progression, compared to the re-
verse strategy, in fit elderly patients with advanced
NSCLC participating in the GFPC0504 study, a rando-
mized phase 2 trial [12].
Patients and methods
Study design and population
The GFPC 0504 study was a multicenter, open-label,
randomized phase II trial. It involved patients with pre-
viously untreated stage IIIB or IV NSCLC. It compared
erlotinib followed, after progression, by weekly chemo-
therapy (docetaxel 30 mg/m² for 6 consecutive weeks
and gemcitabine 900 mg/m2 at weeks 1, 2, 4 and 5, fol-
lowed by a two-week treatment-free period) (Arm A) to
the reverse strategy (arm B). The primary endpoint was
second-progression-free survival. Overall survival was a
secondary endpoint.
Costs
Costs were estimated from perspective the French
health care system, from randomization until death. All
resources consumed during the first and second
treatment lines were prospectively collected on a per
patient basis. Resources consumed were comprised of
chemotherapy drugs, erlotinib, supportive treatments
(including recombinant human erythropoietin, antiemetics,
colony-stimulating factors, antibiotics, management ofadverse effects, etc.), transfusion, and hospitalization for
any reason. The specific unit costs are reported in Table 1
[13,14]. Costs incurred after the second disease progres-
sion period were derived from a representative French
nationwide sample of 428 patients, using chart review to
assess the mean direct monthly cost of NSCLC patient
management after the second line progression [15].
Specifically, the costs included outpatient and inpatient
services, care provision at skilled nursing facilities, out-
patient and inpatient drugs and other medications, nurs-
ing care organization, home health visits (including
medications), and durable medical equipment. Assuming
a yearly increment of 3.5%, one month of palliative care
cost 2324 euros (2011 value).
Utilities
Utilities were derived from UK community population-
based studies in advanced NSCLC [16,17], which used
the standard gamble interview and visual analog scales
to assess quality of life (Table 1).
Cost-utility analysis
The incremental cost-effectiveness ratios (ICER) were
calculated. These ratios correspond to the difference
in costs divided by the difference in effectiveness
(expressed in QALY) between two strategies.
Statistical analysis
Second-progression-free survival was calculated from
randomization to disease progression (after the second
line of treatment if the patients received 2 lines, after
the first line if the patient progressed and did not re-
ceive a second line), or death of any cause, or the last
Table 2 Patients characteristics: Arm A: erlotinib followed
by docetaxel plus gemcitabine (DG) after progression;
Arm B: DG followed by erlotinib after progression
(* no significant difference, ** p =0.013)
Arm A Arm B
n=48 n= 51
Age mean (years) 76 ± 5 76 ± 4*
Gender male (%) 29 (60 %) 30 (59 %)*
Smoker 6 (13 %) 8 (16 %)*
Current 26 (54 %) 25 (49 %)
Former 15 (31 %) 15 (29 %)
Never smoker 1 (2 %) 3 (6 %)
Unknown
Performance status 22 (47 %) 21 (41 %)*
0 21 (45 %) 28 (55 %)
1 4 (9 %) 2 (4 %)
2
Stage 6 (13 %) 4 (8 %)*
IIIB 42 (87 %) 47 (92 %)
IV
Histology 11 (23 %) 8 (16 %)**
Squamous cell 28 (58 %) 29 (57 %)
Adenocarcinoma 9 (19 %) 14 (28 %)
Undifferentiated
Second line treatment 29 (60 %) 24 (47 %)**
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randomization to death from any cause, or the last date
the patient was known to be alive. PFS and OS were
assessed by the Kaplan-Meier method. Statistical ana-
lyses used SAS software version 9.01 (Institute INC,
Carry, USA).
Assessing uncertainty
The uncertainty was evaluated by using one-way sensi-
tivity analysis, sequentially varying the estimates for a
given model parameter while keeping the other para-
meters constant, within a range of likely values derived
from confidence intervals or reasonable ranges as deter-
mined from published sources. In addition, multivariate
probabilistic sensitivity analysis was performed using
second-order Monte Carlo simulation, in which the
model inputs (time to second progression, OS, utilities
and costs) were drawn from individual data. Specific
distributions were assigned to utility data by using pub-
lished means and standard deviations to specify the nor-
mal distribution. A simulation with 10 000 replications
of the model was then used to obtain the 95% non-
parametric confidence intervals for the costs and effect-
iveness parameters, and to determine the proportion of
replications in each quadrant of the cost-effectiveness
plane. The multiway sensitivity analysis was presented in
radar screen format, in which the X-axis shows the
difference in effectiveness and the Y-axis the difference
in costs between two strategies. The 10 000 replications
are represented by dots.
Results
Between July 2006 and November 2008, 22 centers en-
rolled 100 patients in this study. Demographic vari-
ables measured int the two groups did not differ in a
statistically way (Table 2). As already reported, there
was no significant difference in the Charlson scores,
co-morbidities, or geriatric assessment scores [12].
There was no significant difference between the two arms
in terms of the time to second progression (5.8 and
7.5 months respectively in arms A and B, p = 0.53) or
median OS (7.1 and 9.4 months, p = 0.26); QALY values
were respectively 0.51± 0.44 and 0.52± 0.41 and costs
were 27 734± 19801 and 31 688± 22693 €. The distribu-
tion of these costs differed between the two arms: pallia-
tive care represented respectively 21.4% and 30.0% of
total costs; chemotherapy 8.6% and 17.6%, and erlotinib
41.5% and 19.7%, in arms A and B (Figure 1). The
Monte Carlo simulation demonstrates that the two
strategies do not differ statistically. Multivariate prob-
abilistic sensitivity analysis (results of 10 000 replications)
showed that the two strategies had equivalent cost-
effectiveness (Figure 2), as confirmed by varying the
utility values and the cost of palliative care (Table 3).Discussion
This analysis showed no significant difference in patient
outcomes between first-line erlotinib followed by
chemotherapy after progression and the reverse se-
quence. However, the erlotinib-first strategy was less
costly, and the ICER of the chemotherapy-first strategy
relative to the erlotinib-first strategy was 395 400 € per
QALY. These results were obtained in a highly specific
population of fit elderly patients selected with a CGA.
The main originality of this study is that the second-line
treatment was fixed in each arm, thus allowing us to
evaluate the performance of the entire treatment strat-
egies. In advanced NSCLC, economic analyses are usu-
ally limited to either first- or second-line treatment.
Sand studies of doublets without platinum salts are rare
in the first-line setting [2].
A study done in Greece [18] compared the docetaxel/
gemcitabin combination with docetaxel monotherapy in
untreated patients with advanced NSCLC. It showed an
incremental cost per life-year gained (LYG) of 9538
euros with the combination. The probability of being
cost-effective was 91% at a threshold of 20 000 euros,
97% at 35 000 euros and 98% at 50 000 euros.
Figure 1 Per patient mean cost in Arm A (erlotinib followed by docetaxel and gemcitabine (DG) and Arm B (DG followed by erlotinib).
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placebo [19] was explored by using resource utilization
determined from individual patient data in the BR.21 trial
database (a pivotal trial in this setting). The trial involved
731 patients (488 in the erlotinib arm and 243 in the
placebo arm). The ICER of erlotinib was $94 638 per LYG
(95% confidence interval = $52 359 to $429 148). The
major drivers of cost-effectiveness included the magnitude
of the survival benefit and the cost of erlotinib. Subgroup
analyses suggested that erlotinib might be more cost-
effective in never-smokers. There was no specific analysis
of elderly patients included in this study.Figure 2 Multivariate probabilistic sensitivity analysis (rresult of 10 00
gemcitabine (DG); Arm B: DG followed by erlotinib (ICE: incremental cost eThe cost-effectiveness of erlotinib has also been com-
pared with that of other agents (docetaxel and peme-
trexed) licensed for second-line treatment of advanced
NSCLC [20]. In a model-based analysis, second-line
treatment with erlotinib, docetaxel and pemetrexed
yielded respectively 0.42, 0.41, and 0.41 QALY, and total
costs were US$ 37 000, 39 100 and 43 800. Again, there
was no specific analysis of elderly patients. A more re-
cent cost-utility analysis compared erlotinib and doce-
taxel for second-line management of advanced NSCLC
within the UK National Health Service. The authors
used a health-state transition model, based on the two0 replications). Arm A: erlotinib followed by docetaxel and
ffectiveness).
Table 3 One way sensitivity analysis
Arm A Arm B ICER B/A
Costs € / utility Costs €/ utility €/QALY
Base case 27 734 €/0.51 31 688 €/ 0.52 395400
Utility of patients
treated by erlotinib
−20% (0.538) 27 734 €/ 0.48 31 688 €/ 0.51 131800
−10% (0.606) 27 734 €/0.51 31 688 €/ 0.52 395400
+10% (0.740) 27 734 €/ 0.54 31 688 €/ 0.54 NA
+20% (0.807) 27 734 €/ 0.57 31 688 €/ 0.55 NA
Post-progression cost
1627 € 25 954 €/ 0.51 28 787 €/ 0.52 283300
3021 € 29 514 €/ 0.51 34 588 €/ 0.52 507400
Erlotinib tariff
−30% 24 282 €/ 0.51 29 788 €/ 0.52 550600
+ 30% 31 186 €/ 0.51 33 588 €/ 0.52 240200
Arm A: erlotinib followed by docetaxel and gemcitabine (DG); Arm B: DG
followed by erlotinib.
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portive care and docetaxel versus best supportive care,
to estimate direct costs, QALY, and the subsequent net
monetary benefit. Erlotinib was associated with lower
total costs (£13 730 versus £13 956) and a gain in
QALY [16]. In a recently, retrospective real world cost-
effectiveness study, on second line setting, erlotinib
and docetaxel are statistically equivalent in terms of
treatment costs and overall survival [21].
Regarding the burden of NSCLC in terms of health-
related quality of life, little information is available on
the preferences of patients or society with respect to dis-
ease states [22,23]. We used data from Nafees et al. [17],
who adapted existing health-state descriptions in meta-
static breast cancer to evaluate the utilities of patients
receiving second-line treatment for NSCLC. Each health
state describes the symptom burden of a disease and its
functional impact. More recently, Lewis [16] used the
same method to establish health utilities for erlotinib
therapy, based on data for 154 members of the UK gen-
eral population, using the euroQol EQ-5D instrument.
We used the results of both studies to test the robust-
ness of our model with varying utility values.
One advantage of our study is the prospective collec-
tion of cost data, at least until second progression. In
contrast, management costs after the end of active treat-
ments were derived from a 2004 national database. In
addition, our analysis was limited to direct lung cancer-
related medical costs: indirect costs such as lost prod-
uctivity and caregiver salaries were not included. Also,
the way in which we expressed utilities reflects the value
from the point of view of society rather than that of the
patients concerned. Finally, it is uncertain whether theseutilities are fully relevant to our population of elderly
patients. However, our sensitivity analyses compensated
for these limitations, as the conclusions based on the
base-case scenario were unaffected when we varied the
different model parameters. One limitation of our ana-
lysis is that EGFR patients status was not knew and we a
unable to analyze the ICER of erlotinib first line treat-
ment in the subgroup of patient with a EGFR mutation.
Conclusion
In terms of cost-effectiveness, in fit elderly patients with
NSCLC, erlotinib followed by chemotherapy compares
well with the reverse strategy.
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